Journal of

Background and Aim: Skin cancer is the most common malignancy in the world with high morbidity and relatively low mortality. Basal cell carcinoma (BCC) is the most common type of cancer and its incidence is increasing. The purpose of this study was to investigate the incidence of skin cancer in the years 1386 to 1390 is in the Markazi Province, Iran.

Methods: In this study the data of Markazi Province Cancer Registry were used and incidence rate was calculated per 100,000 person. Age standardized incidence rates were calculated via direct standardization method using world standard population. Finally, the data were analyzed using SPSS, Excel, and WinPepi softwares.

Results: In Markazi Province, 958 patients with skin cancer were recorded during 1386-90. The age-standardized incidence rates in these years were 21.54, 12.06, 13.79, 18.29 and 15.79 per 100,000 people respectively. There was no significant change in the trend of skin cancer incidence rates.

Conclusion: Skin cancer was higher in men than women, and most cases occur in the elderly. Development of screening programs is recommended to detect skin cancer in its early stages in older men, especially in those who have been exposed to the sun for long times.

Background and aim: As the use of botulinum toxin to treat glabellar lines increases, particularly in Iran, where foreign products (e.g. Dysport) are relatively expensive, it becomes important to compare the efficacy, side effects, and duration of action of two locally produced botulinum toxin brands, Masport® and Dyston®. This study seeks to assess and compare the treatment results of these two medications.
 

Methods: In this cross-sectional, descriptive, retrospective study, the medical records of 81 patients who visited Razi Dermatology Hospital for the treatment of moderate to severe glabellar lines were reviewed. Data related to patient satisfaction, duration of action, and side effects of Masport® and Dyston® botulinum toxin were collected and analyzed via a questionnaire.
 

Results: The mean satisfaction score was 7 for the Dyston® group and 7.7 for the Masport® group, with no statistically significant difference between the two groups (P=0.142). Additionally, the mean duration of action was 3.5 months for Dyston® and 3.8 months for Masport®, with no significant difference observed. Headache was the most common side effect reported, with no other major adverse events noted. Furthermore, there was no statistically significant difference in the incidence of side effects between the two groups.
 

Conclusion: The findings of this study indicate that both Dyston® and Masport® have similar efficacy and safety profiles. The choice between them can be primarily based on cost and patient or physician preference rather than any significant therapeutic differences. Larger studies are recommended to further validate these findings.